"Many Scientists aspire to help discover and develop a life changing therapeutic for a significant unmet medical need. At Genentech, we have had the privilege of helping to make this a reality for thousands of patients. To be a part of this mission is both humbling and inspiring."
After completing my Ph.D. at UCSC and Postdoctoral fellowship at Stanford, I joined Genentech in 1993 as a Scientist to help develop a new field studying the Pharmacokinetics and Pharmacodynamics of protein therapeutics. I was drawn to Genentech because of its great scientific reputation and it offered me the best opportunity to pursue great science in the mission of helping patients.
Over my career at Genentech, I have had the privilege of contributing to the discovery and development of multiple therapeutics, as well as, the training and development of our next generation of scientists and drug developers.
Journal of Pharmacology and Experimental Therapeutics. 2008 Nov;327(2):308-15.
Journal of Clinical Endocrinology & Metabolism. 87(10):4508-14, 2002 Oct.
I am currently leading 2 groups focused on Preclinical and Translational Pharmacology for all therapeutic areas and Biomarkers and Diagnostics for our non-oncology pipeline. These groups contribute to the preclinical and clinical development of molecules in multiple therapeutic areas, as well as, to the basic science of Pharmacokinetics, Systems Pharmacology and Biomarkers/Diagnostics.
Together our major goals are to develop state of the art “Translational Pharmacology” and “Biomarker” tools, data, and analyses to help enter the clinical development with both the knowledge and tools to maximize clinical success, to enable informed decision-making, and to enable our PHC mission. Ultimately our data helps ensure we give the right drug at the right dose to the right patients.